StockNews.AI
TRVI
StockNews.AI
49 days

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

1. Trevi Therapeutics is developing Haduvio for chronic cough treatment. 2. Haduvio shows significant cough frequency reduction in clinical trials. 3. Chronic cough affects ~150,000 IPF patients in the U.S. 4. No approved therapies exist for chronic cough conditions in the U.S. 5. Management to present at Leerink Partners forum on July 8-9.

6m saved
Insight
Article

FAQ

Why Bullish?

Haduvio's potential for significant market impact in unmet medical needs boosts TRVI's profile. Previous biopharmaceutical stocks with groundbreaking treatments have seen price surges upon positive trial results or market introductions.

How important is it?

This news highlights Trevi's unique position in a market lacking effective chronic cough therapies, increasing its appeal to investors. The attendance at a reputable conference also suggests proactive engagement with stakeholders, which can enhance market confidence.

Why Long Term?

As Haduvio progresses through clinical trials and toward potential approval, it may drive sustained investor interest and stock appreciation. Long-term prospects hinge on successful outcomes and eventual market introduction.

Related Companies

VRTXGILDREGNBMRN
, /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will be attending Leerink Partners Therapeutics Forum: I&I and Metabolism, held from July 8-9 in Boston, Massachusetts. About Trevi Therapeutics, Inc.    Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC.  Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.  Chronic cough is a highly prevalent condition, impacting up to 85% of patients with IPF. There are ~150,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them.  Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.  For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.  Investor Contact  Katie Barrett  Trevi Therapeutics, Inc.  (203) 903 9627  [email protected] Media Contact  Rosalia Scampoli  914-815-1465  [email protected] SOURCE Trevi Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News